Development of a screening tool to assess risk of tardive dyskinesia.
This article gives an overview of antipsychotic medication and of tardive dyskinesia (TD). It examines the research available on TD as it relates to people with a learning disability (PWLD). The evidence identifies that specific groups of people are at an increased risk of developing TD. It also shows that 45-50% of PWLD who are treated with antipsychotic medication will be affected by TD. The evidence is used in the formulation of an assessment tool designed for use by the community learning disability nurse to identify an individual's risk of developing TD before commencing medication. Litigation in the USA has led to a $6.7 m award for sound, clinically effective practice and evidence-based interventions requires that practitioners are accountable for their practice, but are also seen to transform existing services in a way which improves the delivery of quality interventions and care.
Taylor
Jean
J
Black Country Mental Health NHS Trust.
D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004409:Dyskinesia, Drug-Induced / Q000451:nursing*; D005260:Female; D006801:Humans; D008607:Intellectual Disability / Q000188:drug therapy / Q000451:nursing*; D008297:Male; D008875:Middle Aged; D009730:Nursing Assessment; D012307:Risk Factors; D006113:United Kingdom
D014150:Antipsychotic Agents